WO1997029101A1 - Novel cyclic amino acids as pharmaceutical agents - Google Patents
Novel cyclic amino acids as pharmaceutical agents Download PDFInfo
- Publication number
- WO1997029101A1 WO1997029101A1 PCT/US1997/000255 US9700255W WO9729101A1 WO 1997029101 A1 WO1997029101 A1 WO 1997029101A1 US 9700255 W US9700255 W US 9700255W WO 9729101 A1 WO9729101 A1 WO 9729101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- benzyl
- carbon atoms
- straight
- effective amount
- Prior art date
Links
- 0 *OC(CC1(CN)C*CCC1)=O Chemical compound *OC(CC1(CN)C*CCC1)=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- R-_ is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in United States Patent Number 4,024,175 and its divisional United States Patent
- the uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions.
- the compounds are useful in geriatric patients.
- the patents are hereby incorporated by reference.
- R ] _ and R 2 are similar or different and are each independently hydrogen or a group selected from a ⁇ -Cg alkyl, a C ⁇ -C 4 alkoxy, an amino, an aminomethyl, a carboxyl, an alkoxycarbonyl in which the alkoxy is C ⁇ -C ⁇ , a cyano, a tetrazolyl, a methyltetrazolyl, a methylsulfonylamino, a trifluoromethylsulfonylamino, a trifluoromethyl- sulfonylaminomethyl, an N-cyanoacetamide, an N-hydroxyacetamide, an N- (4-carboxy-1, 3-thiazol- 2-yl) acetamide, a ureido, a 2-cyanoguanidino- carbonyl, a 2-cyanoguanidinomethyl, an imidazol-1- yl-carbonyl, and a 3-cyano-2-methylis
- R 7 CR 7 Rg, in which R 7 is hydrogen, a C ⁇ -C ⁇ alkyl or a phenyl, and Rg is a C ] _-C 4 alkyl or a phenyl: or else R 4 and R5 together are either a group of the formula (CH 2 ) n or a group of the formula
- Y is either an oxygen atom, or a sulfur atom, or a carbon atom substituted by a C1-C4 alkyl group, a phenyl or a phenylalkyl in which the alkyl is C- ⁇ -C ⁇ , or a group N—Rg, in which Rg is a hydrogen, a C- ⁇ -C ⁇ alkyl, a phenylalkyl in which the alkyl is -C , a C ⁇ -C ⁇ alkylcarbonyl, a C ⁇ -C 4 alkylcarbonyl, a C- ⁇ -C ⁇ halogenoalkylcarbonyl, a C- ⁇ -C ⁇ polyhalogeno- alkylcarbonyl, a benzoyl, an alphaaminoacyl or an N-protecting group, or R 4 and R5, together with the carbon atom to which they are bonded, form an indane
- R5 is a cycloalkyl or a eyeloalkylmethyl, said cycloalkyl being C3-C-7, which is unsubstituted or substituted by one or more halogen atoms: or R 4 and R 5 are each a cyclopropyl;
- X is an oxygen atom or sulfur atom; and z and t are zero or one is zero and the other is one; and their salts.
- the compounds are disclosed as having the ability to antagonize angiotension II.
- J. Med. Chem.. 38:3772-3779 (1995) covers the syntheses of spiropiperidines as potent and selective non-peptide tackykinin NK 2 receptor antagonists.
- novel cyclic amino acids, their derivatives and pharmaceutically acceptable salts are useful in a variety of disorders.
- the disorders include: epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders
- the compounds are those of formula
- X is O, S, S(O), S(0) 2 , or NR ⁇ wherein R-_ is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms, or benzyl, -C(0)R 2 wherein R 2 is straight or branched alkyl of from 1 to 6 carbon atoms, benzyl, or phenyl, -C0 2 P-3 wherein R3 is straight or branched alkyl of from 1 to 6 carbon atoms, or benzyl wherein the benzyl and phenyl groups can be unsubstituted or substituted by from 1 to 3 substituents each independently selected from halogen, CF , and nitro; and R is hydrogen or lower alkyl .
- Especially preferred compounds of the invention is ⁇ 4-Aminomethyl-tetrahydro-pyran-4-yl) -acetic acid and (4-Aminomethyl-tetrahydro-thiopyran-4-yl) -acetic acid.
- Novel intermediates useful in the preparation of the final products are disclosed as well as a novel process for the preparation of the compounds .
- alkyl is a straight or branched group of from 1 to 6 carbon atoms including but not limited to methyl, ethyl, propyl, n-propyl, isopropyl, butyl, 2-butyl, tert-butyl, pentyl, hexyl, and n-hexyl .
- Lower alkyl is from 1 to 4 carbon atoms including but not limited to methyl, ethyl, propyl, n-propyl, isopropyl, butyl, n-butyl, isobutyl, and tertbutyl .
- the benzyl and phenyl groups may be unsubstituted or substituted by from 1 to 3 substituents selected from halogen, CF3 , and nitro.
- amino acids are amphoteric
- pharmaco ⁇ logically compatible salts when R is hydrogen can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulphuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic.
- salts with alkali metals or alkaline earit metals, for example, sodium, potassium, magnesium, or calcium are formed.
- Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion.
- the carboxyl group of the amino acids can be esterified by known means.
- Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
- Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S ⁇ L) configuration.
- the present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
- the compounds of the invention may be synthesized, for example, by utilizing the general strategy (Scheme 1 below) outlined by Griffiths G., et al . , Helv. Chim. Acta. 74:309 (1991) .
- the compounds may be synthesized by the route outlined by Griffiths G., et al., Helv. Chim. Acta, 74:309 (1991) (Scheme 5 below) .
- the compounds may also be synthesised by the method outlined in Scheme 6 below.
- the X moiety can also be in the 3-position.
- the X moiety can also be in the 3-position Scheme 6
- the X moiety can also be in the 3-position
- the radioligand binding assay using [ 3 H]gabapentin and the ⁇ 2 ⁇ subunit derived from porcine brain tissue was used ("The Novel Anti-convulsant Drug, Gabapentin, Binds to the ⁇ 2 ⁇ Subunit of a Calcium Channel", Gee N. , et al . , J. Biological Chemistry, in press) .
- Table 1 above shows the binding affinity of Example 1 to the ⁇ 2 ⁇ subunit.
- Gabapentin (Neurontin®) is about 0.10 to 0.12 ⁇ M in this assay.
- the compounds of the instant invention are expected, therefore, to exhibit pharmacologic properties comparable to gabapentin. For example, as agents for convulsions, anxiety, and pain.
- the compounds of the invention are related to Neurontin®, a marketed drug effective in the treatment of epilepsy.
- Neurontin® is 1- (aminomethyl) - cyclohexaneacetic acid of structural formula
- the compounds of the invention are also expected to be useful in the treatment of epilepsy. See Table 1 above for IC ⁇ Q data as compared to Neurontin®.
- the present invention also relates to therapeutic use of the compounds of the mimetic as agents for neurodegenerative disorders .
- neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease,
- Parkinson's disease and Amyotrophic Lateral Sclerosis.
- the present invention also covers treating neurodegenerative disorders termed acute brain injury. These include but are not limited to: stroke, head trauma, and asphyxia.
- Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia. A patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like.
- CVA cerebral vascular incident
- the instant invention would be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.
- a skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as suffering from stroke for administration by methods of the present invention.
- the compounds of the invention are also expected to be useful in the treatment of depression.
- Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression.
- the diagnosis of depression is made primarily by quantification of alterations in patients ' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale .
- GABA is an inhibitory neurotransmitter with the central nervous system. Within the general context of inhibition, it seems likely that GABA-mimetics might decrease or inhibit cerebral function and might therefore slow function and decrease mood leading to depression.
- the compounds of the instant invention may produce an anticonvulsant effect through the increase of newly created GABA at the synaptic junction. If gabapentin does indeed increase GABA levels or the effectiveness of GABA at the synaptic junction, then it could be classified as a GABA-mimetic and might decrease or inhibit cerebral function and might, therefore, slow function and decrease mood leading to depression.
- GABA agonist or GABA-mimetic might work just the opposite way by increasing mood and thus, be an antidepressant, is a new concept, different from the prevailing opinion of GABA activity heretofore.
- the compounds of the instant invention are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures .
- mice Male Hooded Lister rats (200-250 g) are obtained from Interfauna (Huntingdon, UK) and male TO mice (20-25 g) are obtained from Bantin and Kingman (Hull, UK) . Both rodent species are housed in groups of six. Ten Common Marmosets (Callithrix Jacchus) weighing between 280 and 360 g, bred at Manchester University Medical School (Manchester, UK) are housed in pairs. All animals are housed under a 12-hour light/dark cycle (lights on at 07.00 hour) and with food and water ad libitum.
- IP intraperitoneally
- SC subcutaneously
- the apparatus is an open-topped box, 45 cm long, 27 cm wide, and 27 cm high, divided into a small (2/5) and a large (3/5) area by a partition that extended 20 cm above the walls (Costall B., et al . , Exploration of mice in a black and white box: validation as a model of anxiety. Pharmacol. Biochem. Behav. , 32:777-785 (1989) ) .
- the small compartment is painted black and the large compartment white.
- the white compartment is illuminated by a 60-W tungsten bulb.
- the laboratory is illuminated by red light.
- the total number of body postures exhibited by the animal towards the threat stimulus (a human standing approximately 0.5 m away from the marmoset cage and staring into the eyes of the marmoset) is recorded during the 2-minute test period.
- the body postures scored are slit stares, tail postures, scent marking of the cage/perches, piloerection, retreats, and arching of the back.
- Each animal is exposed to the threat stimulus twice on the test day before and after drug treatment.
- the difference between the two scores is analyzed using one-way analysis of variance followed by Dunnett's t-test. All drug treatments are carried out SC at least 2 hours after the first (control) threat.
- the pretreatment time for each compound is 40 minutes.
- Rats are trained to press levers for food reward in operant chambers.
- the schedule consists of alternations of four 4-minute unpunished periods on variable interval of 30 seconds signalled by chamber lights on and three 3-minute punished periods on fixed ratio 5 (by footshock concomitant to food delivery) signalled by chamber lights off.
- the degree of footshock is adjusted for each rat to obtain approximately 80% to 90% suppression of responding in comparison with unpunished responding.
- Rats receive saline vehicle on training days .
- the compounds of the instant invention are also expected to be useful in the treatment of pain and phobic disorders (Am. J. Pain Mana ⁇ . , 5:7-9 (1995)) .
- the compounds of the instant invention are also expected to be useful in treating the symptoms of manic, acute or chronic, single upside, or recurring. They are also expected to be useful in treating and/or preventing bipolar disorder (United States Patent Application Number 08/440,570 filed May 15, 1995) .
- the compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms.
- the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intra- cutaneously, subcutaneously, intraduodenally, or intraperitoneally.
- the compounds of the present invention can be administered by inhalation, for example, intranasally.
- the compounds of the present invention can be administered transdermally.
- the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term "preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparation is preferably in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component.
- the drug may be administered three times daily as, for example, capsules of 100 or 300 mg.
- the composition can, if desired, also contain other compatible therapeutic agents.
- the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
- a daily dose range of about 0.01 mg to about 100 mg/kg is preferred.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed.
- Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound.
- the dosage is increased by small increments until the optimum effect under the circumstances is reached.
- the total daily dosage may be divided and administered in portions during the day, if desired.
- Hydrogen chloride gas was bubbled through an ice-cooled solution of the bis nitrile (2.1 g, 0.014 mol) dissolved in ethanol (100 mL) . After standing for 3 days, the mixture was evaporated to dryness.
- Step 4 Lactam A mixture of the cyanoester (0.8 g, 4.1 mmol), ethanolic ammonia (90 mL) and Raney nickel was shaken under hydrogen overnight . The mixture was filtered and the liquor evaporated to dryness. Trituration with ether gave the product 0.55 g (87%), mp 125-127°C. ⁇ -H NMR (CDC1 3 ) 400 MHz: ⁇ 1.60-1.70 (m, 4H) , 2.29 (s, 2H) , 3.25 (s, 2H) , 3.60-3.75 (m, 4H) , 5.85 (bs, IH) . IR (film) ⁇ ma ⁇ cm -1 : 3190, 3100, 2971, 2935, 2852, 1687, 1102.
- Step 5 (4-Aminomethyl-tetrahvdro-pyran-4-yl) -acetic acid
- the lactam (0.45 g , 2.6 mmol) was refluxed in
- the unsaturated ethyl ester (1.0 g, 5.3 mmol) was heated to reflux under nitrogen in nitromethane (50 mL) with tetramethylguanidine (0.5 mL) for
- Step 3 (4-Aminomethyl-tetrahvdro-thiopyran- 4-yl) -acetic acid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09528505A JP2000511877A (en) | 1996-02-07 | 1997-01-02 | New cyclic amino acids as pharmaceuticals |
EA199800682A EA001534B1 (en) | 1996-02-07 | 1997-01-02 | Derivatives of cyclic amino acid or pharmaceutically acceptable salts thereof, pharmaceutical composition and method of treatment depression, panic conditions, states of fear and pain |
PL97328432A PL328432A1 (en) | 1996-02-07 | 1997-01-02 | Novel cyclic amino acids as pharmaceutic agents |
NZ326669A NZ326669A (en) | 1996-02-07 | 1997-01-02 | Thiopyran or pyran derivatives useful as pharmaceutical agents |
AT97901385T ATE218135T1 (en) | 1996-02-07 | 1997-01-02 | CYCLIC AMINO ACID AS PHARMACEUTICAL AGENTS |
SK1067-98A SK282665B6 (en) | 1996-02-07 | 1997-01-02 | Cyclic amino acid and pharmaceutical preparation based on it |
DE69712877T DE69712877T2 (en) | 1996-02-07 | 1997-01-02 | CYCLIC AMINO ACID AS A PHARMACEUTICAL AGENT |
SI9730332T SI0888325T1 (en) | 1996-02-07 | 1997-01-02 | Novel cyclic amino acids as pharmaceutical agents |
DK97901385T DK0888325T3 (en) | 1996-02-07 | 1997-01-02 | Cyclic amino acids as pharmaceutical agents |
IL12556297A IL125562A (en) | 1996-02-07 | 1997-01-02 | Cyclic amino acids and pharmaceutical compositions comprising them |
EP97901385A EP0888325B1 (en) | 1996-02-07 | 1997-01-02 | Novel cyclic amino acids as pharmaceutical agents |
HU9901074A HUP9901074A3 (en) | 1996-02-07 | 1997-01-02 | Tetrahydropyrane and tetrahydrothiopyrane aminoacids and pharmaceutical compositions containing them |
US09/077,053 US5929088A (en) | 1996-02-07 | 1997-01-02 | Cyclic amino acids as pharmaceutical agents |
AU15295/97A AU720628B2 (en) | 1996-02-07 | 1997-01-02 | Novel cyclic amino acids as pharmaceutical agents |
BR9707366A BR9707366A (en) | 1996-02-07 | 1997-01-02 | New cyclic amino acids as pharmaceutical agents |
NO983612A NO983612L (en) | 1996-02-07 | 1998-08-06 | Novel cyclic amino acids as pharmaceutical agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1127896P | 1996-02-07 | 1996-02-07 | |
US60/011,278 | 1996-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997029101A1 true WO1997029101A1 (en) | 1997-08-14 |
Family
ID=21749660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/000255 WO1997029101A1 (en) | 1996-02-07 | 1997-01-02 | Novel cyclic amino acids as pharmaceutical agents |
Country Status (22)
Country | Link |
---|---|
US (1) | US5929088A (en) |
EP (1) | EP0888325B1 (en) |
JP (1) | JP2000511877A (en) |
KR (1) | KR19990082349A (en) |
AT (1) | ATE218135T1 (en) |
AU (1) | AU720628B2 (en) |
BR (1) | BR9707366A (en) |
CA (1) | CA2244708A1 (en) |
CZ (1) | CZ296052B6 (en) |
DE (1) | DE69712877T2 (en) |
DK (1) | DK0888325T3 (en) |
EA (1) | EA001534B1 (en) |
ES (1) | ES2176668T3 (en) |
HU (1) | HUP9901074A3 (en) |
IL (1) | IL125562A (en) |
NO (1) | NO983612L (en) |
NZ (1) | NZ326669A (en) |
PL (1) | PL328432A1 (en) |
PT (1) | PT888325E (en) |
SK (1) | SK282665B6 (en) |
WO (1) | WO1997029101A1 (en) |
ZA (1) | ZA97991B (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999014184A1 (en) * | 1997-09-18 | 1999-03-25 | Warner-Lambert Company | Novel stereoselective processes for the preparation of gabapentin analogues |
WO1999025683A1 (en) * | 1997-11-18 | 1999-05-27 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate |
WO1999031057A1 (en) * | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
WO2003104184A1 (en) | 2002-06-11 | 2003-12-18 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of gaba analogs |
US6833140B2 (en) | 2001-06-11 | 2004-12-21 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US6984659B2 (en) | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
US6992076B2 (en) | 2000-10-06 | 2006-01-31 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US7026351B2 (en) | 2002-03-20 | 2006-04-11 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
US7183259B2 (en) | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
US7432299B2 (en) | 2002-12-13 | 2008-10-07 | Pfizer Inc. | Method of treatment for sexual dysfunction |
WO2009024615A1 (en) * | 2007-08-23 | 2009-02-26 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
EP2156863A2 (en) | 2003-09-12 | 2010-02-24 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
WO2010042759A2 (en) | 2008-10-08 | 2010-04-15 | Kyphia Pharmaceuticals Inc | Gaba conjugates and methods of use thereof |
US7700652B2 (en) | 2003-09-11 | 2010-04-20 | Xenoport, Inc. | Treating urinary incontinence using prodrugs of GABA analogs |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
WO2010084797A1 (en) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | Hetero atom-containing compound |
US7790708B2 (en) | 2001-06-11 | 2010-09-07 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
USRE41920E1 (en) | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US8026279B2 (en) | 2003-10-14 | 2011-09-27 | Xenoport, Inc. | Crystalline form of γ-aminobutyric acid analog |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8062870B2 (en) | 2008-01-25 | 2011-11-22 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
US8114909B2 (en) | 2003-09-17 | 2012-02-14 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
WO2014113299A1 (en) | 2013-01-15 | 2014-07-24 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
WO2014117176A1 (en) | 2013-01-28 | 2014-07-31 | Lopez Hector L | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
EP4227293A2 (en) | 2018-05-14 | 2023-08-16 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528148A (en) * | 2000-03-28 | 2003-09-24 | デロレンゾ、ロバート・ジェイ | Inhibition of a novel calcium injury current formed in nerve cells during injury suppresses neuronal death |
GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
US20040092498A1 (en) * | 2002-08-16 | 2004-05-13 | David Blakemore | Substituted glycine derivatives for use as medicaments |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024175A (en) * | 1974-12-21 | 1977-05-17 | Warner-Lambert Company | Cyclic amino acids |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
KR970010173B1 (en) * | 1991-07-09 | 1997-06-21 | 닛뽕소다 가부시끼가이샤 | Heterocyclic cyclohexanedione derivative, production thereof, and herbicide |
US5514801A (en) * | 1992-12-29 | 1996-05-07 | Monsanto Company | Cyclic sulfone containing retroviral protease inhibitors |
GB9314758D0 (en) * | 1993-07-16 | 1993-08-25 | Wyeth John & Brother Ltd | Heterocyclic derivatives |
US5527194A (en) * | 1994-02-02 | 1996-06-18 | Brunswick Corporation | Thrust sensor for marine drives |
US5491152A (en) * | 1994-03-23 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis |
US5760006A (en) * | 1997-06-23 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating psoriasis |
-
1997
- 1997-01-02 PL PL97328432A patent/PL328432A1/en unknown
- 1997-01-02 NZ NZ326669A patent/NZ326669A/en unknown
- 1997-01-02 JP JP09528505A patent/JP2000511877A/en not_active Abandoned
- 1997-01-02 AT AT97901385T patent/ATE218135T1/en not_active IP Right Cessation
- 1997-01-02 WO PCT/US1997/000255 patent/WO1997029101A1/en active IP Right Grant
- 1997-01-02 EA EA199800682A patent/EA001534B1/en not_active IP Right Cessation
- 1997-01-02 BR BR9707366A patent/BR9707366A/en not_active Application Discontinuation
- 1997-01-02 ES ES97901385T patent/ES2176668T3/en not_active Expired - Lifetime
- 1997-01-02 CA CA002244708A patent/CA2244708A1/en not_active Abandoned
- 1997-01-02 KR KR1019980706079A patent/KR19990082349A/en not_active Application Discontinuation
- 1997-01-02 IL IL12556297A patent/IL125562A/en not_active IP Right Cessation
- 1997-01-02 US US09/077,053 patent/US5929088A/en not_active Expired - Fee Related
- 1997-01-02 PT PT97901385T patent/PT888325E/en unknown
- 1997-01-02 DE DE69712877T patent/DE69712877T2/en not_active Expired - Fee Related
- 1997-01-02 CZ CZ19982452A patent/CZ296052B6/en not_active IP Right Cessation
- 1997-01-02 SK SK1067-98A patent/SK282665B6/en unknown
- 1997-01-02 HU HU9901074A patent/HUP9901074A3/en unknown
- 1997-01-02 DK DK97901385T patent/DK0888325T3/en active
- 1997-01-02 AU AU15295/97A patent/AU720628B2/en not_active Ceased
- 1997-01-02 EP EP97901385A patent/EP0888325B1/en not_active Expired - Lifetime
- 1997-02-06 ZA ZA9700991A patent/ZA97991B/en unknown
-
1998
- 1998-08-06 NO NO983612A patent/NO983612L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024175A (en) * | 1974-12-21 | 1977-05-17 | Warner-Lambert Company | Cyclic amino acids |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41920E1 (en) | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
US6465689B1 (en) | 1997-09-18 | 2002-10-15 | Warner-Lambert Company | Stereoselective processes for the preparation of gabapentin analogues |
WO1999014184A1 (en) * | 1997-09-18 | 1999-03-25 | Warner-Lambert Company | Novel stereoselective processes for the preparation of gabapentin analogues |
US6384069B1 (en) | 1997-11-18 | 2002-05-07 | Klinikum Der Albert-Ludwigs-Universitaet | Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate |
WO1999025683A1 (en) * | 1997-11-18 | 1999-05-27 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate |
EP1486487A1 (en) * | 1997-11-18 | 2004-12-15 | Klinikum Der Albert-Ludwigs-Universität Freiburg | Position-4 substituted 2-pyrrolidinone derivatives to reduce the level of extracellular glutamate |
US6984659B2 (en) | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
WO1999031057A1 (en) * | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
US7049305B2 (en) | 2000-10-06 | 2006-05-23 | Xenoport, Inc. | Bile-acid conjugates providing for sustained systemic concentration of drugs |
US7601708B2 (en) | 2000-10-06 | 2009-10-13 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US7601706B2 (en) | 2000-10-06 | 2009-10-13 | Xenoport, Inc. | Bile-acid conjugates providing for sustained systemic concentration of drugs |
US6992076B2 (en) | 2000-10-06 | 2006-01-31 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US6833140B2 (en) | 2001-06-11 | 2004-12-21 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
US7645797B2 (en) | 2001-06-11 | 2010-01-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
US7790708B2 (en) | 2001-06-11 | 2010-09-07 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US9238616B2 (en) | 2001-06-11 | 2016-01-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US7420002B2 (en) | 2001-06-11 | 2008-09-02 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
EP2085087A1 (en) | 2001-06-11 | 2009-08-05 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US8168623B2 (en) | 2001-06-11 | 2012-05-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7560483B2 (en) | 2002-02-19 | 2009-07-14 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US8143437B2 (en) | 2002-02-19 | 2012-03-27 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US7569576B2 (en) | 2002-03-20 | 2009-08-04 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
US7026351B2 (en) | 2002-03-20 | 2006-04-11 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
US7868041B2 (en) | 2002-03-20 | 2011-01-11 | Xenoport, Inc. | Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof |
US7767649B2 (en) | 2002-05-17 | 2010-08-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
US7183259B2 (en) | 2002-05-17 | 2007-02-27 | Xenoport | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
WO2003104184A1 (en) | 2002-06-11 | 2003-12-18 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of gaba analogs |
EP2275401A1 (en) | 2002-06-11 | 2011-01-19 | XenoPort, Inc. | Crystalline 1-{[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid |
US7060727B2 (en) | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
US7432299B2 (en) | 2002-12-13 | 2008-10-07 | Pfizer Inc. | Method of treatment for sexual dysfunction |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
US7700652B2 (en) | 2003-09-11 | 2010-04-20 | Xenoport, Inc. | Treating urinary incontinence using prodrugs of GABA analogs |
EP2156863A2 (en) | 2003-09-12 | 2010-02-24 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
US8114909B2 (en) | 2003-09-17 | 2012-02-14 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
US9150503B2 (en) | 2003-10-14 | 2015-10-06 | Xenoport, Inc. | Crystalline form of γ-aminobutyric acid analog |
US8026279B2 (en) | 2003-10-14 | 2011-09-27 | Xenoport, Inc. | Crystalline form of γ-aminobutyric acid analog |
US8686034B2 (en) | 2003-10-14 | 2014-04-01 | Xenoport, Inc. | Crystalline form of γ-aminobutyric acid analog |
EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US8906412B2 (en) | 2004-11-04 | 2014-12-09 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
US8795725B2 (en) | 2004-11-04 | 2014-08-05 | Xenoport, Inc. | GABA analog prodrug sustained release oral dosage forms |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
WO2009024615A1 (en) * | 2007-08-23 | 2009-02-26 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
US8258179B2 (en) | 2008-01-25 | 2012-09-04 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
US8062870B2 (en) | 2008-01-25 | 2011-11-22 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
US8268887B2 (en) | 2008-10-08 | 2012-09-18 | Feng Xu | Drug conjugates and methods of use thereof |
US9186341B2 (en) | 2008-10-08 | 2015-11-17 | Feng Xu | GABA conjugates and methods of use thereof |
WO2010042759A2 (en) | 2008-10-08 | 2010-04-15 | Kyphia Pharmaceuticals Inc | Gaba conjugates and methods of use thereof |
EP3075722A1 (en) | 2008-10-08 | 2016-10-05 | Xgene Pharmaceutical Inc | Gaba conjugates and methods of use thereof |
US10478412B2 (en) | 2008-10-08 | 2019-11-19 | Xgene Pharmaceutical Inc. | GABA conjugates and methods of use thereof |
WO2010084797A1 (en) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | Hetero atom-containing compound |
WO2014113299A1 (en) | 2013-01-15 | 2014-07-24 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
WO2014117176A1 (en) | 2013-01-28 | 2014-07-31 | Lopez Hector L | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
EP4227293A2 (en) | 2018-05-14 | 2023-08-16 | Xgene Pharmaceutical Inc | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
Also Published As
Publication number | Publication date |
---|---|
ES2176668T3 (en) | 2002-12-01 |
PL328432A1 (en) | 1999-02-01 |
EA199800682A1 (en) | 1999-02-25 |
DE69712877D1 (en) | 2002-07-04 |
PT888325E (en) | 2002-10-31 |
IL125562A0 (en) | 1999-03-12 |
EP0888325A1 (en) | 1999-01-07 |
CZ296052B6 (en) | 2005-12-14 |
HUP9901074A3 (en) | 2001-08-28 |
JP2000511877A (en) | 2000-09-12 |
SK106798A3 (en) | 1999-07-12 |
DE69712877T2 (en) | 2002-11-14 |
NO983612D0 (en) | 1998-08-06 |
CZ245298A3 (en) | 1998-11-11 |
IL125562A (en) | 2001-08-08 |
ATE218135T1 (en) | 2002-06-15 |
HUP9901074A2 (en) | 2001-04-28 |
CA2244708A1 (en) | 1997-08-14 |
EA001534B1 (en) | 2001-04-23 |
KR19990082349A (en) | 1999-11-25 |
EP0888325B1 (en) | 2002-05-29 |
ZA97991B (en) | 1997-08-15 |
AU1529597A (en) | 1997-08-28 |
US5929088A (en) | 1999-07-27 |
NO983612L (en) | 1998-10-06 |
AU720628B2 (en) | 2000-06-08 |
SK282665B6 (en) | 2002-11-06 |
NZ326669A (en) | 2001-05-25 |
DK0888325T3 (en) | 2002-09-16 |
BR9707366A (en) | 1999-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5929088A (en) | Cyclic amino acids as pharmaceutical agents | |
AU731279B2 (en) | Novel bridged cyclic amino acids as pharmaceutical agents | |
AU733896B2 (en) | Substituted gamma aminobutyric acids as pharmaceutical agents | |
CA2244912C (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
EP1045839B1 (en) | Novel amines as pharmaceutical agents | |
US7122678B2 (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
US6518289B1 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
CA2245647C (en) | Novel bridged cyclic amino acids as pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE HU IL IS JP KE KR LC LK LR LS LT LV MG MK MN MW MX NO NZ PL RO SD SG SI SK TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09077053 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2244708 Country of ref document: CA Ref document number: 2244708 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997901385 Country of ref document: EP Ref document number: PA/a/1998/006107 Country of ref document: MX Ref document number: 326669 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-2452 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980706079 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 106798 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800682 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-2452 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997901385 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980706079 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997901385 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980706079 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1998-2452 Country of ref document: CZ |